Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Phenoxybenzamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.94 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.94 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.94 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.94 |
| ▸ | HTR2A | P28223 | 2/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ESR1 | P03372 | 1/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.94 |
| ▸ | HTR1A | P08908 | 1/20 | 0.94 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenoxybenzamine SCHEMBL202823 | 0.97 | SMN1; SMN2 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL5722 | 0.97 | SMN1; SMN2 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL50729 | 0.96 | ALDH1A1 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL14894820 | 0.87 | SMN1; SMN2 (0.81) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL11992656 | 0.84 | ALDH1A1 (0.76) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL15960915 | 0.84 | ALDH1A1 (0.76) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL19958436 | 0.83 | ALDH1A1 (0.74) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11077715 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11682499 | 0.82 | TSHR (0.72) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL7748883 | 0.81 | ALDH1A1 (0.65) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | UNIVERSITAET DES SAARLANDES (DE) | 2016-03-10 | — | — | US | claimed |
| WO-2014173868-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | UNIVERSITAET DES SAARLANDES (DE) | 2014-10-30 | — | — | WO | claimed |
| EP-2796137-A1 | SERCA inhibitor and Calmodulin antagonist combination | Universität des Saarlandes (DE) | 2014-10-29 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| US-10463640-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-11-05 | — | — | US | disclosed |
| US-10441558-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-10-15 | — | — | US | disclosed |
| US-10322101-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-06-18 | — | — | US | disclosed |
| EP-3459535-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2019-03-27 | — | — | EP | disclosed |
| US-20180360785-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-12-20 | — | — | US | disclosed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | ATP2A2, ATP2A1, ATP2A3 | ADRA2B 1061/4885ADRA2C 1794/4885ADRA1A 2297/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRA2B 551/4885ADRA2C 1073/4885ADRA1A 434/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ADRA2B 698/4885ADRA2C 351/4885ADRA1A 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.